There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Veru (VERU) with bullish sentiments.
Veru (VERU)
Cantor Fitzgerald analyst Brandon Folkes maintained a Buy rating on Veru on November 4 and set a price target of $6.00. The company’s shares closed last Monday at $9.70, close to its 52-week high of $10.83.
According to TipRanks.com, Folkes is a 2-star analyst with an average return of 1.5% and a 40.5% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Surgalign Holdings, Aziyo Biologics, and Alkermes.
Veru has an analyst consensus of Strong Buy, with a price target consensus of $12.25, implying a 24.1% upside from current levels. In a report issued on December 13, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.50 price target.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VERU:
